Supply Chain Intelligence

Monte Rosa Therapeutics, Inc. Supply Chain

GLUE supply chain intelligence for Monte Rosa Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

GLUE ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

8Suppliers
9Customers
2Debt Items
20Related Chains

Monte Rosa Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
NVS Novartis AG 90% Any costs for any co-funded development and commercialization activities are subject to budgets reviewed by the Company and Novartis.
NVS Novartis AG 90% Reciprocal relationship from NVS graph: Reciprocal relationship from GLUE graph: Any costs for any co-funded development and commercialization activities are subject to budgets reviewed by the Compan…
CCCC C4 Therapeutics, Inc. 72% current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t…
CCCC C4 Therapeutics, Inc. 72% Reciprocal relationship from CCCC graph: Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alter…
KYMR Kymera Therapeutics, Inc. 72% Reciprocal relationship from KYMR graph: Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alter…
KYMR Kymera Therapeutics, Inc. 72% current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t…
NVSEF Novartis AG 72% delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects. In addition, some of our suppliers are located outside of the…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLUE graph: delay, limit or prevent our development efforts, which could harm our business, results of operations, financial con…

Monte Rosa Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
NVS Novartis AG 92% Reciprocal relationship from NVS graph: Reciprocal relationship from GLUE graph: Reciprocal relationship from NVS graph: Reciprocal relationship from GLUE graph: Pursuant to the 2025 Novartis Agreeme…
NVS Novartis AG 92% Pursuant to the 2025 Novartis Agreement, we granted to Novartis an exclusive, royalty-bearing, sublicensable and transferable license to degraders for one I&I program, or the First Licensed Program
ROCHE ROCHE 90% Pursuant to the License Agreement, the parties will seek to identify and develop MGDs against cancer or neurological disease targets using our proprietary drug discovery platform for an initial set o…
NVSEF Novartis AG 85% Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLUE graph: pany has identified certain performance obligations within the agreement as follows: • Performance obligations for t…
NVSEF Novartis AG 85% pany has identified certain performance obligations within the agreement as follows: • Performance obligations for the research and development of initial targets • Performance obligations for the re…
CCCC C4 Therapeutics, Inc. 72% Reciprocal relationship from CCCC graph: Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alter…
CCCC C4 Therapeutics, Inc. 72% current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t…
KYMR Kymera Therapeutics, Inc. 72% Reciprocal relationship from KYMR graph: Reciprocal relationship from GLUE graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from GLUE graph: current or future product candidate…
KYMR Kymera Therapeutics, Inc. 72% current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t…

Monte Rosa Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
GLUE-DEBT Debt stack $39.1M 90% Market cache reports total debt of $39.1M.
GLUE-DEBT-9808 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-06-30.

Monte Rosa Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Monte Rosa Therapeutics, Inc..

Monte Rosa Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
GLUE-OWNER-NEA-MANAGEMENT-COMPANY-LLC NEA Management Company, LLC 90% 13F overlay lists NEA Management Company, LLC as top holder; 191 tracked holders.

Monte Rosa Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
GILD Gilead Sciences, Inc. 100.00 2
JBIO Jade Biosciences, Inc. 100.00 2
HLNCF Haleon plc 100.00 2
BNBX BNB Plus Corp. 100.00 2
HLN Haleon plc 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CRIS Curis, Inc. 100.00 2
COLL Collegium Pharmaceutical, Inc. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
AZN AstraZeneca PLC 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
ABT Abbott Laboratories 100.00 2
SLGL Sol-Gel Technologies Ltd. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
ELVN Enliven Therapeutics, Inc. 100.00 2
KLRS Kalaris Therapeutics, Inc. 100.00 2
View GLUE supply chain intel →

Explore the full interactive supply chain map for Monte Rosa Therapeutics, Inc..

Open GLUE supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map